MCID: NNL001
MIFTS: 42

Non-Langerhans-Cell Histiocytosis

Categories: Rare diseases, Immune diseases

Aliases & Classifications for Non-Langerhans-Cell Histiocytosis

MalaCards integrated aliases for Non-Langerhans-Cell Histiocytosis:

Name: Non-Langerhans-Cell Histiocytosis 12 49 14
Histiocytosis, Non-Langerhans-Cell 72 49 41 69

Classifications:



External Ids:

Disease Ontology 12 DOID:4330
MeSH 41 D015616
SNOMED-CT 64 127069007
UMLS 69 C0019624

Summaries for Non-Langerhans-Cell Histiocytosis

MalaCards based summary : Non-Langerhans-Cell Histiocytosis, also known as histiocytosis, non-langerhans-cell, is related to juvenile xanthogranuloma and reticulohistiocytic granuloma. An important gene associated with Non-Langerhans-Cell Histiocytosis is CD163 (CD163 Molecule), and among its related pathways/superpathways are Lysosome and Cholesterol and Sphingolipids transport / Distribution to the intracellular membrane compartments (normal and CF). The drugs Busulfan and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, testes and bone marrow, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia : 72 Non-Langerhans cell histiocytosis refers to a family of histiocytosis characterized by the absence of... more...

Related Diseases for Non-Langerhans-Cell Histiocytosis

Diseases related to Non-Langerhans-Cell Histiocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Related Disease Score Top Affiliating Genes
1 juvenile xanthogranuloma 32.6 BRAF DES F13A1
2 reticulohistiocytic granuloma 32.0 CD163 CD207
3 erdheim-chester disease 30.8 BRAF SST
4 langerhans cell histiocytosis 30.3 BRAF CD163 CD207 F13A1
5 fibromatosis 30.2 ACTC1 DES
6 fibroblastic rheumatism 30.1 ACTC1 CD163 DES F13A1
7 histiocytosis 29.6 BRAF CD163 CD207 IL1RN SMPD1
8 histiocytosis, progressive mucinous 11.3
9 ovarian fibrothecoma 10.5 ACTC1 DES
10 cutaneous leiomyosarcoma 10.5 ACTC1 DES
11 myofibroma 10.5 DES F13A1
12 spindle cell lipoma 10.5 ACTC1 DES
13 progressive nodular histiocytosis 10.5 ACTC1 F13A1
14 parachordoma 10.5 ACTC1 DES
15 ossifying fibromyxoid tumor 10.4 ACTC1 DES
16 epithelioid leiomyosarcoma 10.4 ACTC1 DES
17 benign metastasizing leiomyoma 10.4 ACTC1 DES
18 scleromyxedema 10.4 ACTC1 F13A1
19 congenital fibrosarcoma 10.4 ACTC1 DES
20 pulmonary vein stenosis 10.4 ACTC1 DES
21 cystic nephroma 10.4 ACTC1 DES
22 pleomorphic liposarcoma 10.4 ACTC1 DES
23 ischemic fasciitis 10.4 ACTC1 DES
24 perivascular epithelioid cell tumor 10.4 ACTC1 DES
25 reticulum cell sarcoma 10.4 ACTC1 DES
26 niemann-pick disease type c, severe perinatal form 10.4 NPC1 NPC2
27 niemann-pick disease type c, late infantile neurologic onset 10.4 NPC1 NPC2
28 niemann-pick disease type c, severe early infantile neurologic onset 10.4 NPC1 NPC2
29 spindle cell sarcoma 10.4 ACTC1 DES
30 niemann-pick disease type c, adult neurologic onset 10.4 NPC1 NPC2
31 niemann-pick disease type c, juvenile neurologic onset 10.4 NPC1 NPC2
32 pseudosarcomatous fibromatosis 10.4 ACTC1 DES
33 glomus tumor 10.4 ACTC1 DES
34 niemann-pick disease, type c1 10.4 NPC1 NPC2
35 acid sphingomyelinase deficiency 10.4 NPC1 SMPD1
36 binswanger's disease 10.3 ACTC1 SST
37 infantile myofibromatosis 10.3 ACTC1 DES
38 smooth muscle tumor 10.3 ACTC1 DES
39 chondromyxoid fibroma 10.3 ACTC1 DES
40 angiolipoma 10.3 ACTC1 DES F13A1
41 myopericytoma 10.3 ACTC1 BRAF
42 dedifferentiated liposarcoma 10.3 ACTC1 DES F13A1
43 hemangiopericytoma, malignant 10.3 ACTC1 DES F13A1
44 malignant fibroxanthoma 10.3 ACTC1 DES F13A1
45 adenofibroma 10.2 ACTC1 BRAF
46 botryoid rhabdomyosarcoma 10.2 ACTC1 DES
47 villous adenoma 10.2 BRAF SST
48 fasciitis 10.2 ACTC1 DES
49 histiocytic sarcoma 10.1 BRAF CD163
50 cavernous sinus meningioma 10.1 CD163 CD207

Graphical network of the top 20 diseases related to Non-Langerhans-Cell Histiocytosis:



Diseases related to Non-Langerhans-Cell Histiocytosis

Symptoms & Phenotypes for Non-Langerhans-Cell Histiocytosis

MGI Mouse Phenotypes related to Non-Langerhans-Cell Histiocytosis:

43 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.15 IL1RN CD163 NPC1 DES ACTC1 F13A1
2 cardiovascular system MP:0005385 10.13 IL1RN CD163 NPC1 DES ACTC1 F13A1
3 cellular MP:0005384 10.11 IL1RN CD163 NPC1 DES ACTC1 BRAF
4 behavior/neurological MP:0005386 10.1 HEXA BRAF DES NPC2 PITX3 NPC1
5 growth/size/body region MP:0005378 10.09 BRAF IL1RN ACTC1 HEXA NPC2 PITX3
6 hematopoietic system MP:0005397 10.06 IL1RN CD163 CD207 NPC1 F13A1 BRAF
7 immune system MP:0005387 9.97 IL1RN CD163 CD207 NPC1 BRAF PITX3
8 mortality/aging MP:0010768 9.85 IL1RN NPC1 DES ACTC1 F13A1 HEXA
9 liver/biliary system MP:0005370 9.73 BRAF HEXA PITX3 NPC1 SMPD1 NPC2
10 reproductive system MP:0005389 9.5 BRAF IL1RN F13A1 HEXA PITX3 NPC1
11 respiratory system MP:0005388 9.17 CD163 NPC1 F13A1 BRAF PITX3 SMPD1

Drugs & Therapeutics for Non-Langerhans-Cell Histiocytosis

Drugs for Non-Langerhans-Cell Histiocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 130)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 3,Phase 2,Early Phase 1 55-98-1 2478
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
3
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
4
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
5
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 657311 5754
6
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
7
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
8
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
9
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
10
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
11
Miglustat Approved Phase 3,Phase 2,Phase 1 72599-27-0 51634
12
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 83-43-2 6741
13
Prednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 50-24-8 5755
14
Asparaginase Approved, Investigational Phase 3 9015-68-3
15
Pegaspargase Approved, Investigational Phase 3 130167-69-0
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
17
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
18
Butyric Acid Experimental, Investigational Phase 3,Phase 2 107-92-6 264
19
Doxil Approved June 1999 Phase 3,Phase 2 31703
20
1-Deoxynojirimycin Experimental Phase 3,Phase 2 19130-96-2 1374
21 Alkylating Agents Phase 3,Phase 2
22 Anti-Bacterial Agents Phase 3,Phase 2
23 Antibiotics, Antitubercular Phase 3,Phase 2
24 Antiemetics Phase 3,Phase 2,Phase 1
25 Antifungal Agents Phase 3,Phase 2,Phase 1
26 Anti-Infective Agents Phase 3,Phase 1,Phase 2
27 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
28 Antilymphocyte Serum Phase 3,Phase 2
29 Antimetabolites Phase 3,Phase 2
30 Antimetabolites, Antineoplastic Phase 3,Phase 2
31 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
32 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
33 Antirheumatic Agents Phase 3,Phase 2,Phase 1
34 Antitubercular Agents Phase 3,Phase 2
35 Autonomic Agents Phase 3,Phase 2,Phase 1
36 BB 1101 Phase 3,Phase 2
37 Calcineurin Inhibitors Phase 3,Phase 2,Phase 1
38 Cortisol succinate Phase 3,Phase 2
39 Cyclosporins Phase 3,Phase 2,Phase 1
40 Dermatologic Agents Phase 3,Phase 2,Phase 1
41 Dexamethasone acetate Phase 3,Phase 2 1177-87-3
42 Etoposide phosphate Phase 3,Phase 2
43 Folic Acid Antagonists Phase 3,Phase 2
44 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
45 glucocorticoids Phase 3,Phase 2,Phase 1
46 Hormone Antagonists Phase 3,Phase 2,Phase 1
47 Hormones Phase 3,Phase 2,Phase 1
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
49 Hydrocortisone 17-butyrate 21-propionate Phase 3,Phase 2
50 Hydrocortisone acetate Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 80)

# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis Unknown status NCT00334672 Phase 3 busulfan;cyclophosphamide;cyclosporine;dexamethasone;etoposide;methotrexate;mycophenolate mofetil;therapeutic hydrocortisone
2 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
3 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
4 L-DEP as an Initial Treatment for EBV-HLH Recruiting NCT02912702 Phase 3 Pegaspargase;doxorubicin hydrochloride liposome injection;etoposide;methylprednisolone;Etoposide;dexamethasone
5 Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology Recruiting NCT02862054 Phase 2, Phase 3
6 L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis Recruiting NCT02631109 Phase 3 Pegaspargase;doxorubicin;etoposide;methylprednisolone
7 A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis Recruiting NCT01818492 Phase 2, Phase 3
8 Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Recruiting NCT02004691 Phase 2, Phase 3 placebo (saline);GZ402665
9 Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004 Active, not recruiting NCT00426101 Phase 3 Dexamethasone;Etoposide;Cyclosporin
10 Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
11 Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
12 Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis Not yet recruiting NCT03312751 Phase 3 Emapalumab
13 T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders Terminated NCT00176826 Phase 2, Phase 3 Myeloablative conditioning regimen
14 Trial of DA-EPOCH Regimen for NHL With HLH Unknown status NCT01818908 Phase 2 DA-EPOCH
15 Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis Completed NCT01104025 Phase 2 ATG, rabbit;Etoposide;Methotrexate;hydrocortisone;Dexamethasone
16 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 Completed NCT02124083 Phase 1, Phase 2 Vorinostat
17 Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine Completed NCT00975689 Phase 1, Phase 2 N-Acetyl Cysteine
18 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
19 Miglustat in Niemann-Pick Type C Disease Completed NCT00517153 Phase 2 miglustat
20 Stem Cell Transplant for Immunologic or Histiocytic Disorders Completed NCT00176865 Phase 2 Fludarabine;Melphalan;Anti-thymocyte globulin (ATG);Campath 1H;Cyclosporin A;Mycophenolate mofetil;Intravenous immunoglobulin (IVIG)
21 Treatment of Familiar Lymphohistiocytosis Recruiting NCT02472054 Phase 1, Phase 2 Alemtuzumab;Methyl Prednisolone (MP);Cyclosporin A (CSA)
22 Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis Recruiting NCT02385110 Phase 2 Alemtuzumab;Etoposide;Dexamethasone;Methotrexate;Tocilizumab
23 Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH) Recruiting NCT02007239 Phase 2 tocilizumab
24 A Study to Investigate the Safety and Efficacy of an Anti-IFN-gamma mAb in Children With Systemic Juvenile Idiopathic Arthritis (sJIA) Developing Macrophage Activation Syndrome/ Secondary Hemophagocytic Lymphohistiocytosis (MAS/sHLH) Recruiting NCT03311854 Phase 2 NI-0501
25 Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Disease Recruiting NCT03201627 Phase 1, Phase 2 Lithium Carbonate
26 Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Vemurafenib
27 Study of Pharmacokinetics and Preliminary Efficacy in Patients With Niemann-Pick C1 Recruiting NCT02912793 Phase 1, Phase 2 Hydroxypropyl-beta-cyclodextrin
28 A Study of Lenalidomide for Adult Histiocyte Disorders Recruiting NCT02523040 Phase 2 Lenalidomide
29 Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency Recruiting NCT02292654 Phase 1, Phase 2 Olipudase alfa
30 Immune Disorder HSCT Protocol Recruiting NCT01821781 Phase 2 Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
31 T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Recruiting NCT00368355 Phase 2 Ara-C;Cyclophosphamide
32 Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C Recruiting NCT03471143 Phase 1, Phase 2 2-Hydroxypropyl-Beta-Cyclodextrin
33 Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204) Active, not recruiting NCT01998633 Phase 2
34 Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Active, not recruiting NCT01372228 Phase 1, Phase 2
35 A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Enrolling by invitation NCT02004704 Phase 2 GZ402665
36 Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease Suspended NCT02281760 Phase 2 Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide
37 Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease Terminated NCT01727206 Phase 2 Tocilizumab
38 Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism Terminated NCT00668564 Phase 2 Cyclophosphamide;Campath-1H;Busulfan
39 Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease Completed NCT01747135 Phase 1 VTS-270
40 Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients Completed NCT01722526 Phase 1 Recombinant human acid sphingomyelinase
41 Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease Completed NCT00316498 Phase 1 OGT918
42 Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1) Recruiting NCT02939547 Phase 1 Hydroxypropyl-beta-cyclodextrin
43 UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Recruiting NCT02254863 Phase 1
44 BMT Abatacept for Non-Malignant Diseases Recruiting NCT01917708 Phase 1 Abatacept
45 Human Placental-Derived Stem Cell Transplantation Active, not recruiting NCT01586455 Phase 1 Human Placental Derived Stem Cell
46 Administration of Donor T Cells With the Caspase-9 Suicide Gene Active, not recruiting NCT01494103 Phase 1 AP1903
47 Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases Terminated NCT02231710 Phase 1
48 Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Terminated NCT00410566 Phase 1 rhASM;rhASM;rhASM;rhASM;rhASM
49 Children and Adult Hemophagocytic Syndrome (HLHa) Unknown status NCT02113917
50 New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome Unknown status NCT01095146

Search NIH Clinical Center for Non-Langerhans-Cell Histiocytosis

Cochrane evidence based reviews: histiocytosis, non-langerhans-cell

Genetic Tests for Non-Langerhans-Cell Histiocytosis

Anatomical Context for Non-Langerhans-Cell Histiocytosis

MalaCards organs/tissues related to Non-Langerhans-Cell Histiocytosis:

38
T Cells, Testes, Bone Marrow, Skin, Eye, Brain, Bone

Publications for Non-Langerhans-Cell Histiocytosis

Articles related to Non-Langerhans-Cell Histiocytosis:

(show all 25)
# Title Authors Year
1
High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. ( 28679734 )
2017
2
Non-Langerhans cell histiocytosis. ( 26739442 )
2016
3
Spontaneous regression of infantile dural-based non-Langerhans cell histiocytosis after surgery: case report. ( 25634822 )
2015
4
Suprasellar non-Langerhans cell histiocytosis (Erdheim-Chester disease)--a case report. ( 23465991 )
2013
5
Retinal manifestations in a patient with xanthoma disseminatum (non-langerhans cell histiocytosis). ( 21484660 )
2011
6
Rare case of infratentorial non-Langerhans cell histiocytosis with lethal outcome presenting multiple diagnostic difficulties. ( 22025140 )
2011
7
Intracranial non-Langerhans cell histiocytosis presenting as an isolated intraparenchymal lesion. ( 20635081 )
2010
8
Endolymphatic non-langerhans cell histiocytosis of the larynx: report of an uncommon disease manifestation. ( 20463609 )
2010
9
Non-Langerhans cell histiocytosis with isolated CNS involvement: an unusual variant of Erdheim-Chester disease. ( 20337948 )
2010
10
Fibroblastic rheumatism: fibromatosis rather than non-Langerhans cell histiocytosis. ( 19615014 )
2010
11
Diffuse xanthogranulomatous dermatitis and systemic Langerhans cell histiocytosis: A novel case that demonstrates bridging between non-Langerhans cell histiocytosis and Langerhans cell histiocytosis. ( 19022530 )
2009
12
Non-Langerhans cell histiocytosis in a child with Kawasaki disease. ( 21686403 )
2009
13
Cerebral non-Langerhans cell histiocytosis in a 17-year-old patient with a headache: case report. ( 19363626 )
2009
14
Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. ( 16020507 )
2005
15
[Erdheim-Chester disease: a non-Langerhans cell histiocytosis. A clinical-case and review of the literature]. ( 15344569 )
2004
16
A child with both Langerhans and non-Langerhans cell histiocytosis. ( 12383099 )
2002
17
Problems in differential diagnosis of non Langerhans cell histiocytosis with pituitary involvement: case report and review of literature. ( 12665654 )
2002
18
Progressive histiocytosis: description of a case of slow-course non-Langerhans cell histiocytosis. ( 12399681 )
2002
19
Primary cerebral non-Langerhans cell histiocytosis: MRI and differential diagnosis. ( 12221448 )
2002
20
Benign cephalic histiocytosis progressing into juvenile xanthogranuloma: a non-Langerhans cell histiocytosis transforming under the influence of a virus? ( 10698221 )
2000
21
Non-Langerhans cell histiocytosis associated with lymphocyte-predominant Hodgkin's disease. ( 10564322 )
1999
22
Generalized non-Langerhans cell histiocytosis: four cases illustrate a spectrum of disease. ( 7737766 )
1995
23
An unusual case of non-Langerhans cell histiocytosis. ( 8294600 )
1994
24
A unique non-Langerhans cell histiocytosis with some features of generalized eruptive histiocytoma. ( 8034797 )
1994
25
Congenital self-healing non-Langerhans cell histiocytosis. ( 3058480 )
1988

Variations for Non-Langerhans-Cell Histiocytosis

Expression for Non-Langerhans-Cell Histiocytosis

Search GEO for disease gene expression data for Non-Langerhans-Cell Histiocytosis.

Pathways for Non-Langerhans-Cell Histiocytosis

Pathways related to Non-Langerhans-Cell Histiocytosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.01 HEXA NPC1 NPC2 SMPD1
2
Show member pathways
10.1 NPC1 NPC2

GO Terms for Non-Langerhans-Cell Histiocytosis

Cellular components related to Non-Langerhans-Cell Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 CD163 F13A1 IL1RN NPC1 NPC2 SMPD1
2 lysosome GO:0005764 9.26 HEXA NPC1 NPC2 SMPD1
3 lysosomal lumen GO:0043202 8.8 HEXA NPC2 SMPD1

Biological processes related to Non-Langerhans-Cell Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 muscle filament sliding GO:0030049 9.4 ACTC1 DES
2 response to cocaine GO:0042220 9.37 PITX3 SMPD1
3 cholesterol transport GO:0030301 9.32 NPC1 NPC2
4 cholesterol efflux GO:0033344 9.26 NPC1 NPC2
5 response to drug GO:0042493 9.26 ACTC1 NPC1 SMPD1 SST
6 low-density lipoprotein particle clearance GO:0034383 9.16 NPC1 NPC2
7 establishment of protein localization to membrane GO:0090150 8.62 BRAF NPC1

Sources for Non-Langerhans-Cell Histiocytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....